Earnings results for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. is expected* to report earnings on 05/06/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.22. The reported EPS for the same quarter last year was $0.04.
Ironwood Pharmaceuticals last posted its quarterly earnings data on February 17th, 2021. The biotechnology company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.27 by $0.09. The firm had revenue of $116.68 million for the quarter, compared to analysts’ expectations of $106.50 million. Ironwood Pharmaceuticals has generated $0.55 earnings per share over the last year and currently has a price-to-earnings ratio of 15.7. Ironwood Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, May 6th, 2021.
Analyst Opinion on Ironwood Pharmaceuticals (NASDAQ:IRWD)
5 Wall Street analysts have issued ratings and price targets for Ironwood Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.40, predicting that the stock has a possible upside of 5.26%. The high price target for IRWD is $14.00 and the low price target for IRWD is $9.00. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of “Hold.”
Ironwood Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings. According to analysts’ consensus price target of $11.40, Ironwood Pharmaceuticals has a forecasted upside of 5.3% from its current price of $10.83. Ironwood Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Ironwood Pharmaceuticals (NASDAQ:IRWD)
Ironwood Pharmaceuticals does not currently pay a dividend. Ironwood Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Ironwood Pharmaceuticals (NASDAQ:IRWD)
In the past three months, Ironwood Pharmaceuticals insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $15,552,210.00 in company stock and sold $0.00 in company stock. Only 2.40% of the stock of Ironwood Pharmaceuticals is held by insiders.
Earnings and Valuation of Ironwood Pharmaceuticals (NASDAQ:IRWD
Earnings for Ironwood Pharmaceuticals are expected to grow by 69.12% in the coming year, from $0.68 to $1.15 per share. The P/E ratio of Ironwood Pharmaceuticals is 15.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.88. The P/E ratio of Ironwood Pharmaceuticals is 15.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 44.12.
More latest stories: here